SUTRO BIOPHARMA, INC. Short-term Lease, Cost
SUTRO BIOPHARMA, INC. (STRO) reported Short-term Lease, Cost of $69.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShortTermLeaseCost · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. short-term lease, cost for the quarter ending 2026-06-30 was $69.00K, a 15.00% increase year-over-year.
- SUTRO BIOPHARMA, INC. short-term lease, cost for the quarter ending 2026-03-31 was $65.00K, a 66.67% increase year-over-year.
- SUTRO BIOPHARMA, INC. short-term lease, cost for the quarter ending 2025-12-31 was $17.00K, a 69.09% decline year-over-year.
- SUTRO BIOPHARMA, INC. short-term lease, cost for the quarter ending 2025-09-30 was $56.00K, a 14.29% increase year-over-year.
- SUTRO BIOPHARMA, INC. short-term lease, cost for fiscal 2025 was $172.00K, a 11.79% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. short-term lease, cost for fiscal 2024 was $195.00K, a 28.83% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. short-term lease, cost for fiscal 2023 was $274.00K, a 234.15% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. short-term lease, cost for fiscal 2022 was $82.00K, a 29.91% decline from fiscal 2021.
| Period end | Short-term Lease, Cost 3 month | Short-term Lease, Cost 6 month | Short-term Lease, Cost 9 month | Short-term Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $69.00K 10-Q · filed 2026-08-12 | $134.00K 10-Q · filed 2026-08-12 | $151.00K derived: sum of 3 quarters · filed 2026-08-12 | $207.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $65.00K 10-Q · filed 2026-05-14 | $82.00K derived: sum of 2 quarters · filed 2026-05-14 | $138.00K derived: sum of 3 quarters · filed 2026-05-14 | $198.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $73.00K derived: sum of 2 quarters · filed 2026-03-23 | $133.00K derived: sum of 3 quarters · filed 2026-08-12 | $172.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $56.00K 10-Q · filed 2025-11-06 | $116.00K derived: sum of 2 quarters · filed 2026-08-12 | $155.00K 10-Q · filed 2025-11-06 | $210.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $60.00K 10-Q · filed 2026-08-12 | $99.00K 10-Q · filed 2026-08-12 | $154.00K derived: sum of 3 quarters · filed 2026-08-12 | $203.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $39.00K 10-Q · filed 2026-05-14 | $94.00K derived: sum of 2 quarters · filed 2026-05-14 | $143.00K derived: sum of 3 quarters · filed 2026-05-14 | $181.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $104.00K derived: sum of 2 quarters · filed 2026-03-23 | $142.00K derived: sum of 3 quarters · filed 2026-03-23 | $195.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $49.00K 10-Q · filed 2025-11-06 | $87.00K derived: sum of 2 quarters · filed 2025-11-06 | $140.00K 10-Q · filed 2025-11-06 | $312.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $38.00K 10-Q · filed 2025-08-07 | $91.00K 10-Q · filed 2025-08-07 | $263.00K derived: sum of 3 quarters · filed 2025-08-07 | $322.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $53.00K 10-Q · filed 2025-05-08 | $225.00K derived: sum of 2 quarters · filed 2025-05-08 | $284.00K derived: sum of 3 quarters · filed 2025-05-08 | $303.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $231.00K derived: sum of 2 quarters · filed 2025-03-13 | $250.00K derived: sum of 3 quarters · filed 2025-03-13 | $274.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $59.00K 10-Q · filed 2024-11-13 | $78.00K derived: sum of 2 quarters · filed 2024-11-13 | $102.00K 10-Q · filed 2024-11-13 | $124.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $19.00K 10-Q · filed 2024-08-13 | $43.00K 10-Q · filed 2024-08-13 | $65.00K derived: sum of 3 quarters · filed 2025-03-13 | $84.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $24.00K 10-Q · filed 2024-05-13 | $46.00K derived: sum of 2 quarters · filed 2025-03-13 | $65.00K derived: sum of 3 quarters · filed 2025-03-13 | $85.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $41.00K derived: sum of 2 quarters · filed 2025-03-13 | $61.00K derived: sum of 3 quarters · filed 2025-03-13 | $82.00K 10-K · filed 2025-03-13 |
| 2022-09-30 | $19.00K 10-Q · filed 2023-11-13 | $39.00K derived: sum of 2 quarters · filed 2023-11-13 | $60.00K 10-Q · filed 2023-11-13 | $104.00K derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $20.00K 10-Q · filed 2023-08-10 | $41.00K 10-Q · filed 2023-08-10 | $85.00K derived: sum of 3 quarters · filed 2024-03-25 | $107.00K derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $21.00K 10-Q · filed 2023-05-15 | $65.00K derived: sum of 2 quarters · filed 2024-03-25 | $87.00K derived: sum of 3 quarters · filed 2024-03-25 | $98.00K derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $66.00K derived: sum of 2 quarters · filed 2024-03-25 | $77.00K derived: sum of 3 quarters · filed 2024-03-25 | $117.00K 10-K · filed 2024-03-25 |
| 2021-09-30 | $22.00K 10-Q · filed 2022-11-08 | $33.00K derived: sum of 2 quarters · filed 2022-11-08 | $73.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $11.00K 10-Q · filed 2022-08-08 | $52.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $41.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |